SIETES :: 92334 citas

Resultados de la búsqueda por POLÍTICAS SANITARIAS REFINAR BÚSQUEDA

1.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

2.

Anónimo. PhRMA lobbying costs surge 30 percent during first year of Trump’s presidency. DIA Daily 2018:7. [Ref.ID 102451]

3.

Hernández-Aguado I, Chilet-Rosell E. Pathways of undue influence in health policy-making: a main actor's perspective. J Epidemiol Community Health 2018;72:154-9. [Ref.ID 102446]

4.

Greene JA, Loscalzo J. Putting the patient back together — Social medicine, network medicine, and the limits of reductionism. N Engl J Med 2017;377:2493-9. [Ref.ID 102185]

5.

Anónimo. Dutch health minister considers compulsory license over drug prices. DIA Daily 2017:1. [Ref.ID 102148]

6.

Anónimo. Justice Department issues emergency scheduling of fentanyl analogues to address growing opioid crisis. DIA Daily 2017:1. [Ref.ID 102131]

7.

Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]

8.

Zaman MJ. Cost saving is nothing to be proud of. BMJ 2017;358:j3428. [Ref.ID 101978]

9.

Anónimo. More doctors disclose payments from drug companies . BMJ 2017;358:30 de junio. [Ref.ID 101667]

10.

Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]

11.

Anónimo. Trump takes a conciliatory tone in meeting with pharmaceutical executives. DIA Daily 2017:1. [Ref.ID 101384]

12.

Anónimo. Markets react as investors try to gauge impact of Trump’s election on healthcare sector. DIA Daily 2016:1. [Ref.ID 100916]

13.

Middleton J, McGrail S, Stringer K. Drug related deaths in England and Wales. BMJ 2016;355:i5259. [Ref.ID 100851]

14.

Sheldon T. Saving antibiotics for when they are really needed: the Dutch example. BMJ 2016;354:i4192. [Ref.ID 100707]

15.

Anónimo. Access to medicines—the status quo is no longer an option. Lancet 2016;388:1250. [Ref.ID 100699]

16.

Anónimo. UN panel questions free market approach to R&D for medicines. DIA Daily 2016:1. [Ref.ID 100664]

17.

Crow D. Poorer countries need rapid access to generic drugs, UN says. Financial Times 2016:1. [Ref.ID 100663]

18.

Anónimo. Pfizer CEO criticizes Clinton prescription drug plan as step towards single-payer. DIA Daily 2016:5. [Ref.ID 100654]

19.

Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71. [Ref.ID 100589]

20.

Anónimo. Cancer drug companies slashing prices following closure of NHS’ Cancer Drugs Fund. DIA Daily 2016:1. [Ref.ID 100585]